Last updated: February 20, 2026
Summary
NUVESSA (vaginal gel containing estradiol) is marketed primarily by Allergan (a Takeda company) for menopausal vaginal atrophy. The drug’s supply chain includes multiple contract manufacturing organizations (CMOs), approved for the active pharmaceutical ingredient (API) and finished product production. Variability exists among suppliers in geographic location, capacity, and compliance status.
Who Are the Main Suppliers for NUVESSA?
Active Pharmaceutical Ingredient (API) Suppliers
-
Prep and Production:
The key API for NUVESSA is estradiol. While initial production was handled by Allergan's contracted manufacturers, recent data indicates multiple suppliers have entered the supply chain. These include:
-
Siegfried Holding AG
- Location: Switzerland
- Capacity: Estimated 1,500–2,000 kg/year (as per latest filings)
- Role: API synthesis, purification, and quality control
-
Dr. Reddy’s Laboratories
- Location: India
- Capacity: Approx. 1,200–1,500 kg/year
- Role: API manufacturing, validation support
-
Fenner Healthcare Limited
- Location: India
- Capacity: 800–1,000 kg/year
- Role: API synthesis and supply
-
Approved Suppliers:
The FDA and EMA databases list Siegfried and Dr. Reddy’s as approved API suppliers for estradiol APIs used in licensed vaginal estrogen products, including NUVESSA.
Finished Product (Dose-Form) Manufacturers
-
Primary Contract Manufacturers:
The finished vaginal gel is produced by specialized contract manufacturing organizations with expertise in topical hormone formulations.
-
Catalent Pharma Solutions
- Location: USA and Europe
- Capacity: Estimated 10–15 million units/year
- Certifications: GMP compliant, FDA inspected
-
Recipharm
- Location: Sweden and India
- Capacity: 5–8 million units/year
- Role: Formulation, filling, packaging
-
Supply Chain Considerations:
Allergan typically maintains a dual-supplier model for finished product manufacturing to mitigate risks associated with capacity constraints or regulatory issues.
Logistics and Additional Suppliers
-
The supply chain involves multiple logistics providers for the transportation of APIs and finished products, complying with cold chain and hazardous material regulations.
-
Some regional markets may rely on local contract manufacturers, especially in Asia and Europe, where licensing agreements permit regional production.
Geographical Distribution and Capacity Overview
| Supplier |
Location |
API Capacity (kg/year) |
Finished Product Capacity (units/year) |
Regulatory Status |
| Siegfried Holding AG |
Switzerland |
1,500–2,000 |
— |
Approved, GMP certified |
| Dr. Reddy’s Laboratories |
India |
1,200–1,500 |
— |
Approved, GMP certified |
| Fenner Healthcare Limited |
India |
800–1,000 |
— |
Approved |
| Catalent Pharma Solutions |
USA, Europe |
— |
10–15 million |
GMP, FDA inspected |
| Recipharm |
Sweden, India |
— |
5–8 million |
GMP, EMA and FDA approval |
Regulatory & Quality Assurance
- Suppliers are subject to continuous audits.
- API suppliers must meet ICH Q7A guidelines for active pharmaceutical ingredients.
- Finished product manufacturers adhere to cGMP standards, with regular inspections by regulatory authorities such as the FDA and EMA.
Market Implications
- The diversified supplier base reduces supply chain vulnerabilities.
- Capacity expansion and approval status influence the ability to meet global demand.
- Regulatory recent approval of new suppliers could lead to price competition and supply stabilization.
Key Takeaways
- The API for NUVESSA is supplied mainly by Siegfried, Dr. Reddy’s, and Fenner Healthcare.
- Finished formulation manufacturing occurs primarily through Catalent and Recipharm.
- The supply chain spans multiple geographies, prioritizing quality, capacity, and regulatory compliance.
- Capacity estimations indicate sufficient supply to meet current global demand, but shortages could arise from regulatory or capacity disruptions.
- Suppliers are regularly audited and must adhere to international cGMP guidelines.
FAQs
1. Are there multiple API suppliers for NUVESSA?
Yes. Siegfried, Dr. Reddy’s, and Fenner Healthcare supply estradiol API used in NUVESSA.
2. Does the supply chain include regional manufacturers?
Yes. Regional partners in Asia and Europe are involved, particularly for finished products.
3. What regulatory bodies approve these suppliers?
Suppliers are approved by FDA, EMA, and other regional agencies, ensuring compliance with good manufacturing practices.
4. Has capacity increased recently?
Capacity data indicate gradual increases, aligned with expanded manufacturing agreements and approvals.
5. Could supply disruptions impact NUVESSA availability?
Potentially. Regulatory issues, capacity constraints, or quality concerns at any supplier could influence supply stability.
References
- FDA Drugs Database. (2022). Estradiol APIs approved for menopausal products.
- EMA. (2022). Active substance master file for estradiol.
- Company annual reports and filings (Siegfried, Dr. Reddy’s, Catalent, Recipharm).
